Peter Rahmer - Dec 31, 2022 Form 3 Insider Report for Relay Therapeutics, Inc. (RLAY)

Role
Title: Chief Corporate Development Officer
Signature
Brian Adams, as Attorney-in-Fact
Stock symbol
RLAY
Transactions as of
Dec 31, 2022
Transactions value $
$0
Form type
3
Date filed
1/5/2023, 05:32 PM
Next filing
Jan 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding RLAY Common Stock 61.7K Dec 31, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding RLAY Stock Option (Right to Buy) Dec 31, 2022 Common Stock 34.4K $5.21 Direct F2
holding RLAY Stock Option (Right to Buy) Dec 31, 2022 Common Stock 98.6K $14.06 Direct F3
holding RLAY Stock Option (Right to Buy) Dec 31, 2022 Common Stock 31.7K $34.25 Direct F4
holding RLAY Stock Option (Right to Buy) Dec 31, 2022 Common Stock 78.5K $20.38 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 40,834 shares underlying restricted stock units ("RSUs") granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting.
F2 Twenty-five percent (25%) of the shares underlying this option vested on February 21, 2021, and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.
F3 Twenty-five percent (25%) of the shares underlying this option vested on June 22, 2021, and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.
F4 The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments commencing on March 26, 2021, subject to the reporting person's continued service with the Issuer through each vesting date.
F5 The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments commencing on January 27, 2022, subject to the reporting person's continued service with the Issuer through each vesting date.

Remarks:

Title: Chief Corporate Development Officer